Patents Examined by John W. Rollins
  • Patent number: 5658768
    Abstract: Triglycerides with more than 40 wt % saturated fatty acids in the 2-position contain considerable amounts of trisaturated triglycerides; these trisaturated triglycerides are removed (reduced) by performing an enzymic conversion with a source providing unsaturated C.sub.18 to C.sub.22 residues, using a 1,3-specific enzyme.
    Type: Grant
    Filed: November 7, 1995
    Date of Patent: August 19, 1997
    Assignee: Loders Croklaan B.V.
    Inventor: Paul Thomas Quinlan
  • Patent number: 5658794
    Abstract: A method for controlling fungal diseases in turfgrasses using a Pseudomonas aureofaciens. The Pseudomonas aureofaciens is particularly useful in inhibiting dollar spot (Sclerotinia homoeocarpa) in turfgrasses. The method is environmentally safe and economical.
    Type: Grant
    Filed: December 7, 1995
    Date of Patent: August 19, 1997
    Assignee: Board of Trustees operating Michigan State University
    Inventors: Muraleedharan G. Nair, Joseph M. Vargas, Jon F. Powell, Amitabh Chandra, Alvin Ronald Detweiler
  • Patent number: 5658765
    Abstract: Disclosed are novel xylanases, a process for producing the enzyme, a microorganism capable of producing the enzyme, a method for the treatment of pulp with the xylanase enzyme, and a process for producing xylose or xylo-oligosaccharide using the enzyme.
    Type: Grant
    Filed: September 6, 1995
    Date of Patent: August 19, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Yoshitaka Noguchi, Kazuko Ikeda, Eiko Masatsuji, Masahiko Seko
  • Patent number: 5659061
    Abstract: The composition, synthesis, and applications of tumor associated protease activated prodrugs of phosphoramide mustard, isophosphoramide mustard and analogs with detoxification functionalities are described. These drugs release a cytotoxic phosphoramide mustard analog following activation by tumor associated proteases and esterases. The general structure for these drugs is: ##STR1## Wherein R1 is a beta-X-ethyl-amino group which may optionally bear substituents on the nitrogen or carbon atoms; wherein X is a good leaving group such as a halogen; R2 is a beta-X-ethyl-amino group which may optionally bear substituents on the nitrogen or carbon atoms; or an amino group (NH.sub.2) which may optionally be substituted. Wherein A is a benzyloxy derivative with one or more acyloxy or acylamino groups in para or ortho portions relative to the phosphoester; and wherein the acyloxy or acylamino groups are not (substituted or unsubstituted) p-guanidino-benzoyloxy groups or p-guanidino-benzoylamino groups.
    Type: Grant
    Filed: April 20, 1995
    Date of Patent: August 19, 1997
    Assignee: Drug Innovation & Design, Inc.
    Inventor: Arnold Glazier
  • Patent number: 5656478
    Abstract: The present invention provides a method of growing smooth muscle cells in a host with the purpose of maintaining natural cellular function by the function of smooth muscle tissue. In this method, smooth muscle cells are freed from isolated smooth muscle tissue then cultured and injected into the host in combination with an extracellular matrix.
    Type: Grant
    Filed: February 25, 1994
    Date of Patent: August 12, 1997
    Assignee: The Regents of the University of California
    Inventors: Emil A. Tanagho, Rajvir Dahiya, Tom F. Lue, Gerald R. Cunha
  • Patent number: 5653981
    Abstract: A pharmaceutical composition for treatment of cancer and other conditions and the prevention of side effects of anticancer chemotherapy and increasing the immune function contains an extract of the plant Nigella sativa.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: August 5, 1997
    Inventor: Rajko D. Medenica
  • Patent number: 5654328
    Abstract: There are provided compositions for, and a method of, treating malignancies which comprise effective amounts of a novel combined therapy comprising a platinum compound and a tellurium or selenium compound, e.g., ammonium trichloro (dioxoethylene-O,O-tellurate), and administering the respective compounds simultaneously or separately.
    Type: Grant
    Filed: December 15, 1994
    Date of Patent: August 5, 1997
    Inventors: Benjamin Sredni, Michael Albeck
  • Patent number: 5653984
    Abstract: Extracts of periwinkle seed, obtained by bioconversion, and compositions containing such extracts display the property of stimulating mitochondrial cell respiration and of stimulating the cell growth of fibroblasts and keratinocytes. Such extracts and compositions also exhibit activity against oxygen free radicals.
    Type: Grant
    Filed: July 11, 1995
    Date of Patent: August 5, 1997
    Assignee: L'Oreal
    Inventors: Pierre Fodor, Gerard Guth, Emmanuelle Maurin
  • Patent number: 5652265
    Abstract: Methods for the production of rhein and rhein derivatives from aloin-containing substances are described. The oxidation of aloe yellow sap to form aloe-emodin is described, as are the further steps used to treat aloe-emodin to form rhein or rhein derivatives. The present invention provides for the production of rhein and rhein derivatives by methods that are more efficient and economical than those used previously.
    Type: Grant
    Filed: March 29, 1995
    Date of Patent: July 29, 1997
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Natale Vittori, Michael Collins
  • Patent number: 5652124
    Abstract: .alpha.-Glycosyl hesperidin, a novel hesperidin derivative wherein equimolar or more D-glucose residues are bound to hesperidin via the .alpha.-bond, is formed by a saccharide-transferring enzyme in a liquid containing hesperidin and .alpha.-glucosyl saccharide. The .alpha.-glycosyl hesperidin is easily recovered from the reaction mixture with a synthetic macroporous resin. .alpha.-Glycosyl hesperidin is superior in water-solubility, substantially tasteless and odorless, free of toxicity, and readily hydrolyzable in vivo into hesperidin and D-glucose to exhibit the physiological activity inherent to hesperidin. Thus, .alpha.-glycosyl hesperidin is favorably usable in vitamin P-enriching agents, foods, beverages, tobaccos, foods, pet foods, pharmaceuticals for susceptive diseases, cosmetics and plastics.
    Type: Grant
    Filed: July 12, 1995
    Date of Patent: July 29, 1997
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Hiromi Hijiya, Toshio Miyake
  • Patent number: 5652137
    Abstract: A process for the preparation of monoterpene compounds (such as perillyl alcohol, aldehyde and .alpha.-terpineol) from limonene is described. The process uses Bacillus stearothermophilus which is effective at high temperatures (55.degree. to 70.degree. C.).
    Type: Grant
    Filed: September 5, 1995
    Date of Patent: July 29, 1997
    Assignee: Board of Trustees operating Michigan State University
    Inventors: Hae Choon Chang, Patrick J. Oriel
  • Patent number: 5650398
    Abstract: Disclosed herein are modified saponins or fractions thereof obtainable by modification of a crude Quillaja saponaria extract or by modification of purified saponins obtainable from a crude Quillaja saponaria extract useful in pharmaceutical compositions for enhancing the transport of pharmacologically active substances across mucous membranes of an animal. Also disclosed are modified saponins having reduced irritability wherein the aldehyde group is reduced and the fatty acid moiety may be removed by hydrolysis. Also disclosed are pharmaceutical compositions comprising the modified saponins of the invention.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 22, 1997
    Assignee: Cambridge Biotech Corporation
    Inventors: Charlotte A. Kensil, Sean Soltysik, Dante J. Marciani, Joanne Recchia
  • Patent number: 5650432
    Abstract: Proanthocyanidin monomers, dimers, polymers, flavonoid, and flavanoid derivatives and related compounds are used for their ability to interfere with bacterial adherence to a surface. Crystalline proanthocyanadin dimer and plant extracts enriched with such compounds are also disclosed.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: July 22, 1997
    Assignee: JLB, Inc.
    Inventors: Edward B. Walker, Richard A. Mickelsen, Jr., Jennifer N. Mickelsen
  • Patent number: 5650317
    Abstract: Described is a substantially purified human breast epithelial cell (Type I HBEC) displaying the following characteristics: variable cell shape; smooth cell colony boundary; deficiency in gap junctional intercellular communication; positive expression of epithelial membrane antigen and keratin 18; negative expression of keratin 14, .alpha.6 integrin and gap junction genes for connexins (Cx26, Cx32 and Cx43); growth promotion by fetal bovine serum; induction by cholera toxin to differentiate into Type II HBEC (prior art); and acquisition of anchorage independent growth by Semian virus 40 transfection. Also described is a method of obtaining the above-identified epithelial cells comprising the steps of: a) development of a mixture of human breast epithelial cells from reduction mammoplasty tissues using the MSU-1 medium; b) eliminating stromal fibroblasts by a trypsin (0.002%) and ethylenediamine tetraacetic acid (0.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: July 22, 1997
    Assignee: Michigan State University
    Inventors: Chia-Cheng Chang, James E. Trosko
  • Patent number: 5648075
    Abstract: The present invention relates generally to an enzymatically generated iodine microbiocide and more specifically to the use of such a microbiocide for the inactivation of pathogenic organisms that are contaminants in sensitive biological materials. The biocidal agent from the enzymatic reaction is free molecular iodine generated so as to (1) establish a minimum level above 10 ppm of free molecular iodine and (2) to establish defined ratios of free molecular iodine to other iodine species such that free molecular iodine comprises at least 10% of the total iodine species present on a molar basis.
    Type: Grant
    Filed: July 19, 1996
    Date of Patent: July 15, 1997
    Assignee: Symbollon Corporation
    Inventors: Jack H. Kessler, James C. Richards
  • Patent number: 5648258
    Abstract: Anthraquinone compounds inhibit methane production by methanogenic bacteria in the rumen of ruminant animals, increasing production of volatile fatty acids and feed utilization efficiency. Preferred anthraquinones are unsubstituted anthraquinone, 1-aminoanthraquinone, 1-chloroanthraquinone, 2-chloroanthraquinone, 2-chloro-3-carboxyanthraquinone, 1-hydroxyanthraquinone, and 9,10-dihydroanthraquinone.
    Type: Grant
    Filed: July 24, 1995
    Date of Patent: July 15, 1997
    Assignee: Bio-Technical Resources
    Inventor: James Martin Odom
  • Patent number: 5648246
    Abstract: This invention relates to a process for the continuous preparation of wort, including the continuous enzymatic conversion of malt in one rotating disc contactor and separation of spent grain from mash in a separation unit. Further, a process for the continuous preparation of wort, including the continuous gelatinization and enzymatic liquefaction of a mixture based on unmalted grain, malt and/or an enzyme source and water in a rotating disc contactor, addition of malt and/or enzyme source to the product obtained, enzymatic conversion of the product obtained and separation of the spent grain from the mash in a separation unit.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: July 15, 1997
    Assignee: Heineken Technical Services B.V.
    Inventor: Christiaan Willem Versteegh
  • Patent number: 5648377
    Abstract: The present invention relates to novel formulations and combinations of lipophilic and hydrophilic antioxidants and the use thereof in the therapeutic, foodstuff, dietetic, and cosmetic fields. These formulations are based on the use of carotenoids, procarotenoids and derivatives thereof with polyphenols of catechic structures. Said formulations, containing a lipophilic antioxidant and an hydrophilic one, can be used in the prevention of physiopatological conditions related at least partially to an over-production of free radicals, particularly aging, atherosclerosis and cancer.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 15, 1997
    Assignee: Indena S.p.A.
    Inventors: Ezio Bombardelli, Paolo Morazzoni
  • Patent number: 5646035
    Abstract: The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 8, 1997
    Assignee: Human Cell Cultures, Inc.
    Inventors: Hayden G. Coon, Francesco Saverio Ambesi-Impiombato, Francesco Curcio
  • Patent number: 5646178
    Abstract: Compounds isolated from plant materials of the genus Vaccinium, which have biological activity measurable as inhibition with adhesion of bacterial cells to surfaces, are described. The specific compounds include procyanidins, leucocyanin and leucodelphinin, and flavonol glucosides including myricetin-3-pyranoside. An exemplary procyanidin compound is a substituted epicatechin-catechin dimer or other polymer. Also described is an extract prepared from plants of the genus Vaccinium, especially cranberries, which is enriched for anti-adhesion activity. The extract is enriched for polyphenol and flavonoid compounds, lacks detectable amounts of simple sugars, has a very low content of benzoic acid relative to raw cranberries, and lacks significant amounts of anthocyanins. Methods for preparing and for using the extract are disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 8, 1997
    Assignee: JLB, Inc.
    Inventors: Edward B. Walker, Richard A. Mickelsen, Jr., Jennifer N. Mickelsen